Document:

EX-10.13

 Exhibit 10.13 

[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and 

(ii) would be competitively harmful if publicly disclosed. 

EXCLUSIVE LICENSE AGREEMENT 

March 25, 2020 
 THIS
AGREEMENT (“Agreement”) is effective as of March 25, 2020 (“Effective Date”), by and between Longwood University (“Longwood”) and Kiromic Biopharma, Inc, a (DELAWARE) corporation, with its principal
place of business located at 7707 Fannin St Suite 140, Houston, TX 77054 (“Company”). 
 RECITALS 

Under research programs funded by Longwood through research conducted by Dr. Amorette Barber, who has developed an invention pertaining to *
which is described and claimed in * and International publication number * as noted in Appendix A. Company desires to enter into an exclusive licensing agreement in the License Field to commercially develop and use the technology covered by Patent
Rights. Longwood is willing to grant such an Agreement subject to the terms and conditions below. 
 For good and valuable consideration,
the sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. EXCLUSIVE LICENSE AGREEMENT GRANT 

1.1    Longwood hereby grants to Company the exclusive right to negotiate a worldwide, royalty-bearing license under Longwood’s
Patent Rights (“License Field”) and is binding and confidential at time of signature. 
 2. PATENT COSTS 

2.1    Company shall pay Longwood a non-refundable Agreement Fee of fifteen thousand dollars
($15,000). 
 2.2    In addition to the Agreement Fee due to Longwood in accordance with Section 2.1, Company shall reimburse
Longwood, within thirty (30) days of receiving an invoice from Longwood, for all reasonable fees and expenses Longwood incurs for the preparation, filing, prosecution and maintenance of Patent Rights (collectively, “Patent Costs”).
This Section 2.2 shall survive any termination or expiration of this Agreement. Upfront filing fees will also be paid by Company to Longwood for the initial international filing fees requested by Company, and as estimated by Longwood, before
the international filing deadline of March 26, 2020. 

  
 -1- 

 2.3    Payment of the Agreement Fee and Patent Costs made hereunder shall be made by
wire transfer of immediately available funds in United States dollars as follows: 
  

	Account Owner:	 Whitham & Cook, P.C. 

	    	 Operating Account 

	    	 11491 Sunset Hills Road. Suite 340 

	    	 Reston, VA 20190 

  

	Beneficiary Bank:	 Atlantic Union Bank 

	    	 240IO Partnership Blvd 

	    	 Ruther Glen, VA 22546 

	    	 ABA Number: 051403164 

 

	Bene Account Number:	 2674240 

	FFC to:	 Whitham & Cook, P.C. 

	    	 n,
        1: - .. - 

2.4    Longwood shall be responsible for preparing, filing, prosecuting and maintaining Patent Rights and making any decisions pertaining
thereto. 
 2.5    Longwood shall instruct the patent counsel prosecuting such Patent Rights to copy Company on patent prosecution
documents that are received from or filed with the United States Patent and Trademark Office. 
 3. CONTEMPLATED LICENSE TERMS 

3.1    Company acknowledges that the exclusive license contemplated in Section 1.1 would include license terms
typical of agreements between academic institutions and industry, including but not limited to: (i) provisions for the payment of reasonable royalties and other compensation to Longwood; (ii) payment by Company of on-going patent costs in all countries covered by the license; (iii) specific time-limited due diligence obligations for the development and commercialization of a product; (iv) product liability
indemnification and insurance provisions acceptable to Longwood’s liability insurance carriers; and (v) Longwood’s affiliates’ and inventors’ right to make and use the subject matter described and/or in Patent Rights and to
permit others at academic and/or not-for-profit institutions to use the subject matter described and/or claimed in Patent Rights for research and educational purposes.

 3.2    In addition to Section 3.1, Longwood’s grant of any license contemplated in Section 1.1 is further contingent
upon the ability of the parties to reach agreement on license language that is consistent with Longwood’s policies, including but not limited to its Conflict of Interest policies. 

3.3    If the technology covered by Patent Rights was invented at least in part with federal funding, Company’s license would also be
subject to the rights, conditions and limitations imposed by U.S. law including without limitation the royalty-free non-exclusive license granted to the U.S. government (see 35 U.S.C. § 202 et seq.
and regulations pertaining thereto) and any relevant regulations and guidelines, including the NIH Policy and Guidelines for Research Tools (64 Fed. Reg. 28205). 

  
 -2- 

 3.4    If the covered technology is improved by Longwood University, such
“Improvements” shall mean any IP or know-how that is either developed, discovered, or applied as a result of utilizing, implementing, or incorporating the licensed technology of which the new IP will
be included in the Agreement under the same terms and conditions as PCT/US2018/052799 with no additional charges to the Licensee. If the covered technology is improved by Kiromic Biopharma, the technology remains and is owned by Kiromic Biopharma,
however, if the funding for the improvement is done at Longwood and is funded by Kiromic Biopharma, such “Improvements” shall be co-owners of the technology (these shall mean any IP or know-how that is either developed, discovered, or applied as a result of utilizing, implementing, or incorporating the licensed technology of which the new IP will be included in the Agreement under the same terms
and conditions as PCT/US2018/052799 with no additional charges to the Licensee). 
 3.5    If the Company terminates seeks to terminate
this Agreement on any grounds, then all the rights and Longwood’s obligations hereunder will cease and Longwood shall be free to license Patent Rights within or outside of the License Field to any other party. 

4. NOTICES 

4.1    Any notice or other communication required under or pertaining to this Agreement shall be given by prepaid, first class, registered
or certified mail (return receipt requested) or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party, as follows: 

In the case of Longwood: 

Roger A. Byrne, Ph.D. 
 Professor
of Biology 
 Dean, Cook-Cole College of Arts and Sciences 

Longwood University 
 201 High
Street, Farmville, VA 23909 
 434-395-2054 

In the case of Company: 

Maurizio Chiriva-Internati, DBSc, PhD 

Kiromic Biopharma, Inc. 
 7707
Fannin St Suite 140 
 Houston, TX 77054 

Notices and payments shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date
as verifiable by legibly dated U.S. Postal Service postmark or dated receipt from a commercial carrier. Either party may change its address under this Section by providing notice as set forth herein. 

  
 -3- 

 5. PROMOTIONAL ACTIVITIES 

5.1    Neither party shall use the name of the other party or of any trustee, director, officer, staff member, employee, student or agent
of the other party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the party or individual whose name is to be
used. For Longwood, such approval shall be obtained from Longwood’s Chief Public Affairs Officer. 
 6. TERMINATION 

6.1    Company shall have the right to terminate this Agreement upon thirty (30) days advance written notice of termination to
Longwood. 
 6.2    If Company shall fail to faithfully perform any of its obligations under this Agreement, including but not limited
to payment of Patent Costs as provided in Section 2.2 and Diligence Requirements as described in Article 4, Longwood may give written notice of default to Company. If Company fails to cure such breach within 180 calendar days of default notice
from Longwood, the ELA granted to Company under this Agreement will automatically terminate and Longwood shall have no further obligations hereunder. 

6.3    Upon expiration, or termination if applicable, of this Agreement, (i) all unreimbursed Patent Costs incurred as of the
termination or expiration date, as applicable, shall become immediately due and payable to Longwood, and (ii) all obligations of the parties shall cease, except those that expressly survive termination or expiration of this Agreement. 

7. DISCLAIMER 

7.1    LONGWOOD MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS AND THE RIGHTS GRANTED HEREUNDER,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND HEREBY DISCLAIMS THE SAME.
SPECIFICALLY, AND NOT TO LIMIT THE FOREGOING, LONGWOOD MAKES NO WARRANTY OR REPRESENTATION (i) REGARDING THE VALIDITY OR SCOPE OF ANY OF THE CLAIM(S), WHETHER ISSUED OR PENDING, OF ANY OF THE PATENT RIGHTS, AND (ii) THAT THE EXPLOITATION OF THE
PATENT RIGHTS OR ANY PRODUCT WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF LONGWOOD OR OF ANY THIRD PARTY. 

  
 -4- 

 8. MISCELLANEOUS 

8.1    This Agreement constitutes the entire understanding of the parties with respect to the subject matter hereof, superseding and
merging any prior oral or written understandings between the parties. This Agreement may be modified or amended only in a writing signed by duly authorized representatives of both parties hereto. Company shall not assign this Agreement without the
prior written consent of Longwood. If any part of this Agreement is adjudged to be invalid or unenforceable, the parties intend that such invalidity shall not affect any other provision hereof. Any waiver or failure of either party to assert a right
hereunder shall not constitute a waiver or excuse a similar failure in any other circumstance. This Agreement shall be governed by and construed in accordance with the laws of Virginia and each party consents to the exclusive jurisdiction and venue
of courts in Richmond, VA, U.S.A. in all disputes relating to this Agreement. Headings in this Agreement are for convenience only and are not intended to be used to interpret or construe this Agreement. 

The remainder of this page is intentionally left blank. 

  
 -5- 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and
delivered by their duly authorized representatives as of the Effective Date hereof: 
  

									
	LONGWOOD UNIVERSITY	 		 	Kiromic BioPharma, Inc
					
	By:	 	/s/ Larissa M. Smith	 		 	By:	 	/s/ Maurizio Chiriva-Internati
					
	Title:	 	Provost & Vice President of Academic Affairs	 		 	Title:	 	CEO
					
	Name:	 	Larissa M. Smith	 		 	Name:	 	Maurizio Chiriva, DBSc, PhD
					
	Date:	 	March 25, 2020	 		 	Date:	 	March 25, 2020

 The remainder of this page is intentionally left blank. 

  
 -6- 

 APPENDIX A 

PATENT RIGHTS 
 * 

The remainder of this page is intentionally left blank. 

  
 -7-EX-10.14

 Exhibit 10.14 

[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively
harmful if publicly disclosed. 
  

							
	 

	  		 	Corporate Address
 Fannin South Professional

Building, Suite 140
 7707 Fannin Street

Houston, Texas 77054
 t: 832.968.4888
	 	                        

  

							
	 Office of Sponsored Programs
	 	            	 	Financial Department	 	            
				
	 University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard
 Houston, Texas 77030

(713) 792 3220
 (“MD Anderson”)
	 		 	Kiromic Biopharma
 Fannin South Professional Building, Suite 140

Houston, Texas 77054
 (832)
968-4888
 (“Kiromic”)
	 	

  

							
	 Title of the Grant
	  	            	 	Isoforms target validation in animal models	  	            

 We are providing this contract which is awarded to 

Professor Robert S. Bresalier M.D., 
 Department of
Gastroenterology, Hepatology and Nutrition (Principal Investigator of subcontract) 
 the University of Texas MD Anderson Cancer Center for the conduct of
the above research grant 
 MD Anderson is a member institution of The University of Texas System, and as such, is a government agency of the State of
Texas, which under the Constitution and the laws of the State of Texas possesses certain rights and privileges, is subject to certain limitations and restrictions, and only has such authority as is granted to it under the Constitution and laws of
the State of Texas. Notwithstanding any provision hereof, nothing in this grant agreement is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of
the rights, remedies, claims, and privileges of the State of Texas. 
 Start and End Dates of Grant Extension: 

 

							
	         
	 	April 1, 2020	 	        	 	Start Date
		 	March 31, 2021	 		 	End Date

 Invoicing Schedule every first of the month. Kiromic will pay MD Anderson monthly for the grant work performed in the prior
month within thirty (30) days of receipt of invoice. All payments for the grant will be made to MD Anderson and Kiromic will send payments to: 

For check payments: 

The University of Texas 

M.D. Anderson Cancer Center 

Attn: Grants and Contracts (RCTS #57823) 

P.O. Box 4266 

Houston, Texas 77210-4266 

For electronic payments: 

FOR ACH DELIVERY 

Bank Routing Number: 111000614 

Account Number: 522292058 

Account Name: Univ. of Texas MD Anderson Cancer Center-Office of Grants and Contracts 

FOR WIRE TRANSFERS 

Bank Routing Number: 021000021 

SWIFT Code: CHASUS33 

General Bank Reference Address: JPMorgan Chase New York, NY 10004 

Account Number: 522292058 

Account Name: Univ. of Texas MD Anderson Cancer Center-Office of Grants and Contracts 

844.KEY.CURE I www.kiromic.com 

Reviewed and Approved by UTMDACC 

  
 -1- 

 To minimize any delays in receiving and applying payments, Kirmoic will use reasonable
efforts provide the following information via email transmission to GC_Payments@mdanderson.org at the time electronic payment is issued to MD Anderson: (a) name of bank submitting payment, (b) amount of payment, (c) RCTS #57823, (d)
MD Anderson investigator Dr. Robert Bresalier, and (e) Kiromic contact name or email regarding the payment. 
 Progress reporting in accordance
with the following schedule 
  

							
	         
	 	July 2020	 	        	 	First reporting date
		 	Oct 2020	 		 	Second reporting date
		 	Jan 2021	 		 	Third reporting date
		 	Mar 2021	 		 	Fourth and Last reporting date
				
		 	$*        	 		 	Direct Costs
		 	$*        	 		 	Indirect Costs
		 	$*        	 		 	Total

 The budget for this project as outlined in the LOI is 

Invoicing contact person: Trish Faulkner – Financial Department 

7707 Fannin Street, Suite 140, Houston, TX 77054; 832-968-4888

  
 -2- 

 1.        BUDGET JUSTIFICATION 

3.1 MD Anderson Cancer Center Personnel - Total: $96,531 
  

																					
	     
	 	Robert S. Bresalier MD, Principal investigator	 	 	    	 	 	 
	Dr. Bresalier is Professor, Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine,
University of Texas MD Anderson Cancer Center, Houston, TX.
				
		 		 				 	 

	Dr. Bresalier is a leading researcher in solid tumor biology, tumor progression and metastasis, and in
tumor-specific markers. He also directs several longstanding National Institutes of Health (NIH)
funded
research programs in cancer screening, early detection, and prevention.
				
		 		 				 	 

	He has led several pivotal national and international chemoprevention trials for prevention of colorectal
neoplasia. He is member of the National Steering Committee of the Prostate, Lung, Colon, and Ovarian
Cancer
Screening Project, and an investigator of the Early Detection Research Network.
				
		 		 				 	 
	Dr. Bresalier will oversee the progression of the project, and will provide scientific guidance for
experimental design, data interpretation, preparation of manuscripts
				
		 	Time Allocation	 				 	 	He will commit a *% effort the Grant Project.
				
		 		 				 	 	He will receive a total of $12,307 for the entire Grant Project.
									
		 		 				 				 	                	 	Salary	 	                	  	Fringe Costs	  	
		 		 				 				 		 	$*	 		  	$*	  	
		 		 				 				 		 	*%	 		  	*%	  	
		 		 				 				 		 	$*	 		  	$*	  	
									
		 		 				 				 		 	Salary	 		  	$*	  	
		 		 				 				 		 	Fringes	 		  	$*2	  	
		 		 				 				 		 	TOTAL	 		  	$*	  	

  
 -3- 

																					
	     
	 	Senior Scientist (TBN)	 	 	    	 	 	 
	He/She should be an expert in immunotherapy, and immunodiagnostic product development, especially
related to the development of novel solutions to treat cancer and an expert in animal models.
				
		 		 				 	 
	He/She will direct and oversee all aspects of the in vivo studies described in the proposal, including
conceptualization and experimental design, troubleshooting, and analysis of results.
				
		 	Time Allocation	 				 	 	He will commit a *% of his time to the Grant Project.
				
		 		 				 	 	The Senior Scientist will receive a total of $* for the Grant Project.
									
		 		 				 				 	                	 	Salary	 	                	  	Fringe Costs	  	
		 		 				 				 		 	$*	 		  	$*	  	
		 		 				 				 		 	*%	 		  	*%	  	
		 		 				 				 		 	$*	 		  	$*	  	
									
		 		 				 				 		 	Salary	 		  	$*	  	
		 		 				 				 		 	Fringes	 		  	$*	  	
		 		 				 				 		 	TOTAL	 		  	$*	  	

  

																					
	     
	 	Technician (TBD)	 	 	    	 	 	 
	This individual will assist the senior scientist with bench work; animal work and with laboratory
management tasks.
				
		 	Time Allocation	 				 	 	He will commit a total of *% of his time to the Grant Project.
				
		 		 				 	 	He will receive a total of $* for the entire Grant Project.
									
		 		 				 				 	                	 	Salary	 	                	  	Fringe Costs	  	
		 		 				 				 		 	$*	 		  	$*	  	
		 		 				 				 		 	*%	 		  	*%	  	
		 		 				 				 		 	$*	 		  	$*	  	
									
		 		 				 				 		 	Salary	 		  	$*	  	
		 		 				 				 		 	Fringes	 		  	$*	  	
		 		 				 				 		 	TOTAL	 		  	$*	  	

  
 -4- 

									
	3.2 Reagents and supplies - Total $*
				
	     
	 	$*	 	                	 	Plasticware, disposables, and general laboratory supplies
				
		 	$*	 		 	A Multiplex Luminex® Assay will be performed to measure the levels of the following human cytokines, which are key in the etiology of the cytokine release
syndrome (CRS): IFN-y, TNF- a, IL-6, and IL10:
				
		 	$*	 		 	The Xenogen IVIS 200 in vivo imaging system will be used to measure tumor burden and CAR T cells expansion in living mice. Fee for service:
				
		 	$*	 		 	TOTAL
	
	3.3 Animals - Total $*
	
	3.3.1 Procurement of 125 NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ mice (70
mice for CD19 studies + 55 mice for the MSLN studies) from The Jackson Laboratory
				
		 	$*	 		 	$*/mouse x* mice - $*
				
		 	$*	 		 	The current per diem pricing is approximately $* per cage. * = $*
				
		 	$*	 		 	TOTAL
	
	3.3.2 Housing care and experimental procedure: the animals will be housed 5 per cage
	
	3.4 Travel: Domestic - Total $*
	
	Summary of Costs
					
		 		 		 	$*	  	Dr. Bresalier
					
		 		 		 	$*	  	Scientist
					
		 		 		 	$*	  	Technician
					
		 		 		 	$*	  	Total Personnel
					
		 		 		 	$*	  	Reagents and supplies
					
		 		 		 	$*	  	Mice
					
		 		 		 	$*	  	Travel domestic
					
		 		 		 	$*	  	Total Direct Costs
					
		 		 		 	*%	  	MDAA’s Indirect costing rate
					
		 		 		 	$*	  	Total Indirect Costs
					
		 		 		 	$*	  	TOTAL GRANT to MDAA

  
 -5- 

									
	Dr. Bresalier’s laboratory will test the efficacy:
				
	     
	 	 1.1 CD19 isoform targeting
  

(and/or other isoforms for hematological diseases)
	 	 	    	 	 	One of the most innovative approaches for relapsed B-ALL and for refractory DLBCL involves the use of adoptive T cells expressing chimeric antigen receptors
(CAR-T) against CD19. About 30%-50% of CD19 CAR T-cell resistant cases are characterized by the loss of detectable
CD19.
		 				 	  
 Epitope loss has been suggested making leukemia cells invisible to the
modified T cells. This causes resistance to approve anti-CD19 CAR T cell therapies, namely Kymriah® and Yescarta®.

		 				 	  
 Our CAR-NKT/T/NK cell therapy
is directed against a CD19 epitope located in exon 3 and therefore retained in the CD19L’Exon2 variant.

		 				 	  
 Therefore, the CAR-T
CD19L’Exon2 therapy we propose to evaluate in this pre- clinical study could be potentially indicated for B-ALL and DLBCL subjects who failed to respond to approved
anti-CD19 CAR T cell therapies, and whose leukemic cells express the CD19L’Exon2 variant and/or alternative targets for non- solid tumor

				
		 	 1.2 Mesothelin isoform targeting
  

(and/or other isoforms for solid tumors)
	 				 	Mesothelin is an attractive immunotherapeutic target for ovarian cancer and malignant pleural mesothelioma. although tumor cells sensitivity to anti- Mesothelin CAR T cells is higher than that of normal tissues due to the increased
target density on the surface of tumor cells, potential on-target/off-tumor effects are still possible, which may cause dose-limiting toxicities particularly to the
pericardium.
		 				 	  
 In the effort to increase the safety profile of Mesothelin-directed
immunotherapies, by analyzing the splice-level data in the TCGA and GTEx repositories, we have found an alternative-spliced transcript of the human Mesothelin gene, which is only expressed by cancer cells.

		 				 	  
 The anti-mesothelin isoform CAR we plan to test in these pre-clinical studies could be therefore potentially developed for more effective and safer therapies for mesothelin-expressing solid malignancies and/or alternative targets for solid tumor.

  
 -6- 

									
	SCOPE OF WORK
				
	     
	 	Aim 1	 	 	    	 	 	to study the in vivo efficacy, i.e. the anti-tumor potency, of new anti-isoform CAR NKTL or NK and T cells with or without anti-PDL1 and; IL2/15 armor; mSTAT5A; Anti-CD47, and the rapamycin-inducible suicide gene
iCas9
				
		 	Aim 2	 				 	to study the bio-distribution, the in vivo expansion, and the tolerability (toxicity) of new anti-isoform CAR NKTL /or NK and T cells with or without anti-PDL1; IL2/15 armor; mSTAT5A;
Anti-CD47, and the rapamycin-inducible suicide gene iCas9
				
		 	Aim 3	 				 	to study the efficacy of in vivo depletion of engineered CAR cells using rapamycin- induced chimeric caspase 9 (iCas9).

  
 -7- 

 Signature Page 
  

					
	The University of Texas M. D. Anderson Cancer Center	 		 	Kiromic Biopharma
	Name of the Institution	 		 	Name of the institution
			
	/s/ Jaime Faias	 		 	/s/ Tony Tontat
	Signature of Authorized Official	 		 	Signature of Authorized Official
			
	2/6/2020	 		 	3/5/2020
	Date	 		 	Date
			
	Jaime Farias    Assistant Director, OSP	 		 	Tony Tontat (CFO)
	Name and Title of Authorized Official	 		 	Name and Title of Authorized Official
			
	Read and Understood:	 		 	Kiromic Biopharma
		 		 	Name of the Institution
			
	/s/Robert Bresalier	 		 	/s/ Scott Dahlbeck
	Robert Bresalier, MD	 		 	Signature of Authorized Official
	Principal Investigator	 		 	
			
	1/20/2020	 		 	05 March 2020
	Date	 		 	Date
			
		 		 	Dr. Scott Dalhbeck (Chief Medical Officer)
		 		 	Name and Title of Authorized Official

  
 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]